OKYO Pharma Limited Webull Corporate Communications Service Platform
11 Mayo 2023 - 6:00AM
RNS Non-Regulatory
TIDMOKYO
OKYO Pharma Limited
11 May 2023
OKYO Pharma Now Participating on the Webull Corporate
Communications Service Platform
Webull's community of active participants can now access OKYO's
profile on the leading mobile-first brokerage platform
London and New York, NY, May 11, 2023 - OKYO Pharma Limited
(LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused
bio-pharmaceutical company which is developing OK-101 to treat dry
eye disease to address the significant unmet need in this
multi-billion-dollar market, is pleased to announce that they are
now participating on the new Webull Corporate Communication
services platform. The OKYO portal on the Webull platform will help
provide the Company with a direct line of communication with its
shareholders while providing OKYO's followers with instant
notifications regarding corporate content like company news,
earnings reports, investor presentations, and more.
"We're excited to participate on Webull's mobile-first brokerage
platform with a unique community-driven experience," said OKYO
Pharma's founder and Chairman, Gabriel Cerrone. "The Webull
platform will enable OKYO Pharma to take advantage of a convenient
and efficient digital communications channel to reach the platform
of active investors while also allowing us to easily share content
with them in real-time."
For current Webull users, be sure to follow OKYO from the Webull
app. To download the app and register for your free Webull account,
visit: https://www.webull.com/introduce.
About Webull
Brokerage services offered through Webull Financial LLC ("Webull
Financial"), an SEC-registered broker-dealer and member of the
Financial Industry Regulatory Authority (FINRA) and the Securities
Investor Protection Corporation (SIPC). Investment advisory
services are offered by Webull Advisors LLC ("Webull Advisors"), a
Securities and Exchange Commission (SEC) registered investment
adviser. Webull Financial and Webull Advisors are affiliates. All
investing is subject to risk, including the possible loss of the
money you invest. Neither entity guarantees profits or protection
from losses.
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences
company admitted to listing on NASDAQ and on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain. For further information, please visit www.okyopharma.com
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide (MAP)
technology to produce a novel long-acting drug candidate for
treating dry eye disease. OK-101 has been shown to produce
anti-inflammatory and pain-reducing activities in mouse models of
dry eye disease and corneal neuropathic pain; and is designed to
combat washout through the inclusion of the lipid 'anchor'
contained in the candidate drug molecule to enhance the residence
time of OK-101 within the ocular environment.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking
statements. These forward-looking statements are not historical
facts but rather are based on the Company's current expectations,
estimates, and projections about its industry; its beliefs; and
assumptions. Words such as 'anticipates,' 'expects,' 'intends,'
'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions
are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject
to known and unknown risks, uncertainties, and other factors, some
of which are beyond the Company's control, are difficult to
predict, and could cause actual results to differ materially from
those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking
statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in
this announcement relate only to events as of the date on which the
statements are made. The Company will not undertake any obligation
to release publicly any revisions or updates to these
forward-looking statements to reflect events, circumstances, or
unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory
authority.
For further information, please visit the Company's website at
www.okyopharma.com
The person who arranged for the release of this announcement on
behalf of the Company was Gary S. Jacob, Ph.D., Chief Executive
Officer of OKYO.
Enquiries:
OKYO Pharma Limited Gary S. Jacob, Chief Executive Officer +44 (0)20 7495 2379
Investor Relations Paul Spencer +44 (0)20 7495 2379
Optiva Securities Limited
(Broker) Robert Emmet +44 (0)20 3981 4173
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADZGMKDMKGFZG
(END) Dow Jones Newswires
May 11, 2023 07:00 ET (11:00 GMT)
Okyo Pharma (LSE:OKYO)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Okyo Pharma (LSE:OKYO)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024